Cannabis Report
Home > Boards > Canadian > Cannabis > Phivida (CNSX:VIDA)

Phivida Launches Sport Line of CBD Beverages

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jcamp212 Member Profile
 
Followed By 4
Posts 447
Boards Moderated 0
Alias Born 08/09/17
160x600 placeholder
jcamp212   Wednesday, 01/03/18 03:31:00 PM
Re: None
Post # of 50 
Phivida Launches Sport Line of CBD Beverages

SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/01/03/VIDA-PHVAF-Phivida-Launches-Sport-Line-of-CBD-Beverages

SANTA MONICA, CA, Jan. 3, 2018 /PRNewswire/ - Phivida Holdings Inc. ("Phivida" as traded as "VIDA:CNX" and "PHVAF") is pleased to announce the launch of its flagship line of high performance Nano-CBD™ (nanoencapsulated-cannabidiol) infused beverages into the US athletic and sports medicine market.



Phivida Nano-CBD™ Sport line of beverages are designed to maximize physical, mental performance for athletes, fitness professionals and everyday health conscious consumers. The Phivida Nano-CBD™ product lineup incorporates full-spectrum hemp oil in combination with a proprietary blend of organic, plant based nutraceuticals rich in CBD and other non-psychoactive phytocannabinoids, terpenes and flavonoids.



Phivida Nano-CBD™ is designed to enhance bioavailability at an estimated 400%+ higher absorption rate of cannabinoids to achieve a faster acting, longer lasting, and timed release effect within the body. Encapsulated cannabinoids are quickly becoming the preferred delivery method among naturopathic clinicians and integrated sports therapists for strength training and recovery regiments. Nano-CBD™ full spectrum hemp oil extract, could prove to be a powerful antioxidant, neuroprotectant and anti-inflammatory.



Each proprietary blend was developed by a team of scientific experts, including registered nutritionists, cannabinoid pharmacologists in conjunction with Phivida Clinical Advisory Team (led by the former President of the British Columbia College of Naturopathic Doctors), the former Chief Food Science Technician from Dole Juices (later sold to PepsiCo.) and a Health Canada recognized Quality Assurance Professional. Phivida Nano-CBD™ is cGMP certified and 3rd party tested for safety, potency and efficacy.



Phivida Nano-CBD™ functions as a holistic suite of daily preventive health and competitive performance enhancement. Focus is ideal pre-workout or mental preparation for high intensity, Protect is custom designed to enhanced performance during competition or peaks of high stress and activity and Relax is used to modulate mood and provide rest and rejuvenation or post training recovery.



Focus (Orange-Grapefruit) is designed to heighten mental alertness, cognition and memory, Protect (Rasp-Blueberry) targets stress relief, anti-inflammation; immune defence and nervous system protection, and Relax(Pom-Cranberry) aims to modulate mood, stress and sleep.



Dr. Brian Martin, practicing ND and the former President of the BC College of Naturopaths stated; "Phivida's Nano-CBD™ infused functional foods and natural health products provides a therapeutic dose of cannabinoids and meet professional standards of QA/C and third-party lab tests for safety and efficacy which provides licensed naturopathic doctors a greater level of comfort when recommending products to patients and fellow alternative health care practitioners."



The World Anti-Doping Agency ("WADA") recent announcement to remove CBD from the banned substance list opens Phivida products to a global emerging market of sports medicine, competitive athletes, multinational supplement retailers[1] (e.g. CVS, Wholefoods, GNC) and thousands of licensed healthcare clinics[2]. The announcement gives way to athletes for the first time in the history of competitive sports to take CBD and potentially replace toxic opiates and other harmful pharmaceuticals with a natural alternative to manage pain without risk of addiction, side-effects, or serious health complications.



About Cannabidiol ("CBD")



A 2013 literature review published in the British Journal of Clinical Pharmacology, CBD studies include exploration into the following medical properties: Anti-convulsion, inflammation, anxiety, and nausea in animal studies, antitumor activity on human breast carcinoma by inhibiting cancer cell growth. Cannabinoids, (especially CBD) are widely studied for their general preventative and therapeutic effects on inflammation based disorders such as; pain, anxiety, insomnia, appetite, and researched for their potentially curative properties on; glandular cancer (brain, breast, thyroid, prostate, etc.) and Neurodegenerative diseases (MS, Alzheimer's, Epilepsy, etc.). The lack of psychoactivity of CBD-rich hemp varieties make it an appealing treatment option for patients seeking natural plant treatments without the side-effects of THC and the fact that Phivida uses hemp derived CBD from permitted farms protected under the 2014 Farm Bill and Cole Memorandum, Vida+ products are eligible for sale in alternative health care clinics across the United States.



Safe Harbour



This press release contains "forward-looking information" within the meaning of Canadian securities laws, which may include, but are not limited to, statements relating to the Company's use of the proceeds of the Offering and the trading date of the Common Shares. Such forward-looking information reflects Phivida's views with respect to future events and is subject to risks, uncertainties and assumptions, including those set out in the Prospectus. Phivida does not undertake to update forward-looking statements or forward-looking information, except as required by law. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Common Shares have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any common shares in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. We seek safe harbour.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist